Estrella Immunopharma, Inc. — Form 8-K Summary
Reporting date: March 4, 2024; filed March 6, 2024. The filing reports entry into a material definitive agreement and does not provide period-end financial statements or operating results.
Business Context
Estrella Immunopharma, through its wholly owned operating subsidiary Estrella Biopharma, entered into Statement of Work No. 001 with Eureka Therapeutics, Inc. Eureka is the Company’s controlling shareholder and the licensor of the ARTEMISTM T-cell technology used in EB103.
The agreement covers clinical-trial services for EB103, a CD19-targeted T-cell therapy being evaluated in a Phase I/II trial for patients with relapsed or refractory B-cell non-Hodgkin lymphoma. Services include study start-up, site activation, patient enrollment and dosing, data collection, pharmacovigilance, study close-out and reporting.
Financial and Contractual Metrics
- Total non-refundable milestone fees: $33.0 million, assuming 20 patients are dosed and one clinical site is activated.
- Additional potential fee: $500,000 if a second site is activated by mutual agreement.
- Initial invoice upon execution: $3.5 million for study initiation, first-site preparation and activation, and the First Patient First Visit milestone.
- Pre-dosing deposit: $1.5 million, applied against the final invoice; any unused amount is to be returned after outstanding fees and costs are collected.
- Patient-dosing fees: $1.375 million per patient, or $27.5 million for 20 patients, excluding pass-through costs and additional expenses.
- Study close-out milestone: $2.0 million, estimated for completion by the end of 2025.
- Additional pass-through costs, expenses and applicable governmental charges are payable by Estrella Biopharma.
- Invoices are payable within 30 days; Eureka may charge monthly interest of 1.5% on undisputed amounts unpaid after 30 days.
The filing does not provide the Company’s revenue, profit or loss, cash flow, margins, debt, cash balance, liquidity or available financing.
Material Changes, Outlook and Risks
- The SOW establishes a planned dosing schedule of six patients by the end of 2024 and an additional 14 patients by the end of 2025.
- Eureka must provide monthly progress and results updates.
- Eureka, as controlling shareholder, agreed to cooperate in reasonable actions intended to facilitate financing sufficient to fund the SOW, subject to Nasdaq rules and applicable law. The filing does not identify committed financing or establish that adequate funds are currently available.
- Estrella Biopharma may suspend or terminate the SOW but remains responsible for services rendered, expenses and non-cancellable commitments through termination.
- Eureka may suspend deliverables or terminate services if payment terms are not met and disclaims liability for resulting losses or expenses.
- The arrangement is a related-party transaction because Eureka controls the Company. Investors should consider the associated conflicts of interest and funding dependence.
- Clinical development, patient enrollment, site activation, regulatory requirements, trial outcomes and financing availability may delay or prevent achievement of the stated milestones. The filing provides no assurance that the trial timeline or clinical objectives will be met.
Key Facts to Verify
- Whether the $3.5 million initial invoice and $1.5 million deposit have been paid or remain payable.
- The Company’s current cash resources, financing commitments and ability to fund the potential $33.0 million of milestone fees and related costs.
- The full SOW and Services Agreement, including omitted confidential provisions and related-party terms.
- Actual site activation, patient enrollment and dosing progress compared with the projected 2024–2025 schedule.
- Any subsequent amendments, financing transactions, payment defaults, service suspensions or termination notices.
- Clinical-trial status, regulatory developments and emerging safety or efficacy results for EB103.